CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
SB-240563 (Mepolizumab)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00292877
NCT00292877Phase 2Completed
CompareCT.gov

The Effects of a Humanized Anti-IL-5 Monoclonal Antibody (SB-240563) on Asthma Control, Airway Eosinophilia and the Degree to Which Corticosteroid Treatment Can be Reduced to Maintain Control

St. Joseph's Healthcare Hamilton·interventional·Posted Feb 16, 2006·Updated Jan 24, 2011

In Brief

A Phase 2 clinical trial evaluating SB-240563 (Mepolizumab) for Asthma. Completed, across 1 site.

Detailed Summary

The purpose of this study is to determine if treatment with anti-IL-5 antibody has a prednisone-sparing effect in patients with symptomatic eosinophilic bronchitis (with or without asthma).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesCanada
CollaboratorsGlaxoSmithKline

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 16, 2006
Enrollment StartJan 1, 2005
Primary CompletionJun 1, 2008
Study CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 20.4 years ago

Interventions

SB-240563 (Mepolizumab)drug